Financial Survey: IceCure Medical (NASDAQ:ICCM) vs. Westaim (OTCMKTS:WEDXF)

IceCure Medical (NASDAQ:ICCMGet Rating) and Westaim (OTCMKTS:WEDXFGet Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Insider & Institutional Ownership

0.0% of Westaim shares are held by institutional investors. 4.2% of Westaim shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares IceCure Medical and Westaim’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IceCure Medical $4.14 million N/A -$9.90 million N/A N/A
Westaim $2.36 million 117.29 $28.21 million $0.19 10.21

Westaim has lower revenue, but higher earnings than IceCure Medical.

Profitability

This table compares IceCure Medical and Westaim’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IceCure Medical N/A N/A N/A
Westaim 1,188.31% 10.12% 8.68%

Analyst Recommendations

This is a summary of current ratings and recommmendations for IceCure Medical and Westaim, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IceCure Medical 0 0 3 0 3.00
Westaim 0 0 0 0 N/A

IceCure Medical presently has a consensus target price of $7.58, suggesting a potential upside of 210.20%. Given IceCure Medical’s higher possible upside, equities analysts clearly believe IceCure Medical is more favorable than Westaim.

Summary

Westaim beats IceCure Medical on 6 of the 9 factors compared between the two stocks.

About IceCure Medical (Get Rating)

IceCure Medical Ltd research, develops, and markets minimally invasive cryoablation systems for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.

About Westaim (Get Rating)

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.

Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.